Table 2. miR-183-96-182 cluster in tumor invasion, migration, and metastasis.
| Member of miR-183-96-182 cluster | Oncogene/Tumor suppressor | Target genes | Cell lines | Cancer types | Results |
|---|---|---|---|---|---|
| miR-183-96-182 | Oncogene | RAB21(miR-183) RAB40B(miR-96 and miR-183) TNFSF11(miR-96) |
MCF-7, T47D | Breast cancer* | Promote migration [3]. |
| miR-183-96-182 | Oncogene | BRMS1L | MCF-7, T47D, MDA-MB-435s, MDA-MB-468 | Breast cancer* | Promote EMT and invasion [15]. |
| miR-183-96-182 | Oncogene | -- | R262, R300 UW402, UW426, D341, D384, D425, D458, D556, D283, DAOY | Medulloblastoma | Promote migration [155]. |
| miR-183-96-182 | Oncogene | FOXO1 | Hep3B, SNU387, HKCI-1, HKCI-8 | Hepatocellular carcinoma | Promote migration [13]. |
| miR-183-96-182 | Tumor suppressor | FOXF2 | 55 human NSCLC cell lines | Lung cancer | Inhibit invasion and metastasis [116]. |
| miR-183, miR −96 | Tumor suppressor | SLUG, ZEB1, ITGB1, and KLF4 | HCT116, MCF10A | Colon cancer*** | Inhibit EMT, migration, and invasion [9]. |
| miR-96, miR-182 | Oncogene | EFNA5 | HepG2, Hep3B, Huh7, SK-Hep1 | Hepatocellular carcinoma | Promote invasion [85]. |
| miR-183 | Oncogene | -- | HTori-3, FTC-133 | Follicular thyroid carcinomas | Promote migration [171]. |
| miR-183 | Oncogene | PDCD4 | Eca109, TE13 | Esophageal cancer | Promote invasion [76]. |
| miR-183 | Oncogene | PDCD4 | SGC-7901 | Gastric cancer** | Promote invasion [78]. |
| miR-183 | Oncogene | PDCD4 | SW1990 | Pancreatic cancer | Promote invasion and migration [80]. |
| miR-183 | Oncogene | SOCS-6 | PANC-1 | Pancreatic cancer | Promote invasion and metastasis [157]. |
| miR-183 | Oncogene | SOCS-6 | HepG2, Hep3B | Hepatocellular carcinoma | Promote invasion [158]. |
| miR-183 | Oncogene | PP2A-Cα, PP2A-Cβ, and PP2A-B56-γ | ACHN, A498 | Renal cancer | Promote migration and invasion [104]. |
| miR-183 | Oncogene | EGR1 and PTEN | SYO-1, FUJI, HCT116, DLD1, Rh30, JR1 | Synovial sarcoma, RMS, and colon*** cancer | Promote migration [105]. |
| miR-183 | Oncogene | NEFL | U251 | Glioma | Promote invasion [156]. |
| miR-183 | Tumor suppressor | TIAM1 | SKOV-3ip, HO-8910PM | Ovarian cancer | Inhibit migration and invasion [124]. |
| miR-183 | Tumor suppressor | BMI1 | AGS, SGC7901, MKN28, MGC803, HGC27 | Gastric cancer** | Inhibit invasion [103]. |
| miR-183 | Tumor suppressor | EZR | MGC-803, SGC-7901, BGC-823, MKN-45, MKN-28 | Gastric cancer** | Inhibit invasion [120]. |
| miR-183 | Tumor suppressor | EZR | SOSP-9607, and MG63, U2OS, Saos2, HOS, SV40 | Osteosarcoma | Inhibit migration and invasion [118, 119]. |
| miR-183 | Tumor suppressor | EZR | MDA-MB-231, T47D, SKBR-3, ZR-75-1 | Breast cancer* | Inhibit migration [121]. |
| miR-183 | Tumor suppressor | EZR | 801D, 95C | Lung cancer | Inhibit migration [122]. |
| miR-183 | Tumor suppressor | MMP-9 | Siha, HeLa | Cervical carcinoma | Inhibit invasion and metastasis [172]. |
| miR-183 | Tumor suppressor | ITGB1 and KIF2A | HeLa | Cervical carcinoma | Inhibit migration and invasion [125]. |
| miR-96 | Oncogene | RECK | MDA-MB-231, MCF-7, MDA-MB-468, MDA-MB-435, T-74D, MDA-MB-453 | Breast cancer | Promote invasion [83]. |
| miR-96 | Oncogene | MAP4K1 and IRS1 | T24 | Bladder cancer | Promote invasion [108]. |
| miR-96 | Oncogene | -- | AGS | Gastric cancer | Promote invasion [7]. |
| miR-96 | Oncogene | -- | HCCLM6 | Hepatocellular carcinoma | Promote invasion [107]. |
| miR-96 | Oncogene | AKT1S1 | DU145, PC3, LNCap, 22Rv1, RasB1, AC1, AC3 | Prostate cancer | Promote bone metastasis [106]. |
| miR-96 | Tumor suppressor | KRAS | HPDE, BxPC-3, PK-8, and MIA PaCa-2, PANC-1, BxPC-3 | Pancreatic cancer | Inhibit migration and invasion [20, 51]. |
| miR-182 | Oncogene | MTSS1 | HLE, HLF, HepG2, Hep3B, HUH-1 | Hepatocellular carcinoma | Promote invasion [173]. |
| miR-182 | Oncogene | CYLD | LN382T, A172, T98G, LN18, LN229, LN464, SNB19, U373MG, U87MG, LN444, LN443, LN428, U118MG, LN-Z308, LN319 | Glioma | Promote invasion [8]. |
| miR-182 | Oncogene | RECK | MCF-7, MDA-MB-231, SKBR3, BT-20 | Breast cancer | Promote tumorigenicity and invasion [12]. |
| miR-182 | Oncogene | MIM | 4T1 series, MCF10 series | Breast cancer | Promote invasion and metastasis [174]. |
| miR-182 | Oncogene | PFN1 | MDA-MB-231 | Breast cancer | Promote invasion [168]. |
| miR-182 | Oncogene | -- | DAOY, D458 Med, Med8A | Medulloblastoma | Promote migration [175]. |
| miR-182 | Oncogene | RSU1, MTSS1, PAI1, and TIMP1 | STS-48, STS-109, STS-145, primary mice sarcomas cell lines (Kras and p53 mutation) | Sarcomas | Promote migration, invasion and metastasis [176]. |
| miR-182 | Oncogene | -- | Primary mice sarcomas cell lines | Sarcomas | Promote metastasis [18]. |
| miR-182 | Oncogene | CHL1 | TPC-1, BCPAP | Papillary thyroid carcinoma | Promote invasion [161]. |
| miR-182 | Oncogene | SATB2 | DLD-1, HCT116, SW480, SW620, Lovo | Colorectal cancer | Promote migration, invasion and metastasis [162]. |
| miR-182 | Oncogene | FOXF2 | HT29, SW480, SW620, HCT116 | Colorectal cancer | Promote invasion [71]. |
| miR-182 | Oncogene | TSP-1 | HCT-116, HT-29 | Colon cancer | Promote metastasis [177]. |
| miR-182 | Oncogene | PDCD4 | A549 | Lung cancer**** | Promote invasion [56]. |
| miR-182 | Oncogene | PDCD4 | OVCAR3, SKOV3, OV2008, HEY, 3AO, A2780, HO8910, C13 | Ovarian cancer | Promote invasion [77]. |
| miR-182 | Oncogene | BRCA1, MTSS1, and HMGA2 | SKOV3, HEY, OVCAR-3 | Ovarian cancer | Promote invasion and metastasis [178]. |
| miR-182 | Oncogene | MITF and FOXO3 | SK-MEL-19, -29, -85, -94, -100, -103, -147, -173, -187, -192, -197. 501mel, B16F10, WM35 | Melanoma | Promote migration, invasion and metastasis [35]. |
| miR-182 | Oncogene | -- | -- | Melanoma | Promote metastasis [109] |
| miR-182 | Oncogene | CADM1 | GBC-SD | Gallbladder cancer | Promote migration, invasion and metastasis [11]. |
| miR-182 | Oncogene | NDRG1 | LNCap, PC-3, DU145, 22Rv1 | Prostate cancer***** | Promote invasion [126]. |
| miR-182 | Oncogene | FOXF2, RECK and MTSS1 | LNCaP, PC-3, DU145 | Prostate cancer***** | Promote invasion [72]. |
| miR-182 | Oncogene | RECK and SMAD4 | J82, T24, UM-UC-3 | Bladder cancer | Promote invasion and metastasis [169]. |
| miR-182 | Tumor suppressor | FOXO3 | A549, H1299, CL 1-0, CL 1-5 | Lung cancer**** | Inhibit migration and invasion [16]. |
| miR-182 | Tumor suppressor | GNA13 | PC3, LNCaP | Prostate cancer***** | Inhibit invasion [123]. |
Contradictory findings were marked as the same number of *.
Abbreviations: AKT1S1: AKT1 substrate 1; BMI1: BMI1 proto-oncogene; BRCA1: Breast cancer 1, early onset; BRMS1L: Breast Cancer Metastasis Suppressor 1-like; CADM1: Cell adhesion molecule 1; CHL1: Cell adhesion molecule L1-like; CYLD: Cylindromatosis; EGR1: Early growth response 1; EZR: Ezrin; FOXO: Forkhead box O; FOXF2: Forkhead box F2; GNA13: G-protein subunit α-13; HMGA2: High mobility group AT-hook 2; IRS1: Insulin receptor substrate 1; ITGB1: Integrin, beta 1; KIF2A: Kinesin heavy chain member 2A; KLF4: Kruppel-like factor 4; KRAS: Kirsten rat sarcoma viral oncogene homolog; MAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1; MIM: Missing in Metastasis; MMP-9: Matrix metallopeptidase 9; MITF: Microphthalmia-associated transcription factor-M; MTSS1: Metastasis suppressor 1; NDRG1: N-myc downstream regulated 1; PDCD4: Programmed cell death 4; PFN1: profilin 1; PP2A: Protein phosphatase 2A; PTEN:Phosphatase and tensin homolog; RECK: Reversion-inducing-cysteine-rich protein with kazal motifs; PAI1:; Plasminogen activator inhibitor-1; RSU1: Ras suppressor protein 1; SATB2: SATB homeobox 2; SLUG: Snail family zinc finger 2; SMAD4: SMAD family member 4; SOCS-6: Suppressor of cytokine signaling 6; TIAM1: T-cell lymphoma invasion and metastasis 1; TIMP1: Tissue inhibitor of metalloproteinases 1; TSP-1: Thrombospondin-1; ZEB1: Zinc finger E-box binding homeobox 1